Literature DB >> 23770975

The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.

Béatrice Clémenceau1, Régine Vivien, Catherine Pellat, Michael Foss, Gilles Thibault, Henri Vié.   

Abstract

To take advantage of the large number of well-characterized mouse immunoglobulins (IgGs) for the study of antibody-dependent cell-mediated cytotoxicity (ADCC) in human cells, we armed human cytotoxic lymphocytes with a mouse receptor for the Fc portion of IgG antibodies. The human ΝΚ-92 natural killer cell line was transduced with a mouse receptor gene (mCD16), which was stably expressed on the cell surface (referred to as NK-92 (mCD16) ). When tested against a B-lymphoblastoid cell line (BLCL) coated with mouse anti-CD20 IgG1, IgG2a or IgG2b monoclonal antibodies (mAbs), the newly expressed mouse Fc receptor enabled the NK-92 (mCD16) cells to kill the BLCL by ADCC. Next, using the NK-92 (mCD16) we compared mouse mAbs directed at B lineage specific CD antigens for their ability to induce ADCC against human Epstein-Barr virus- infected B lymphoblastoid (for anti-CD19, -CD20 and -CD21) or against myeloma (for anti-CD38 and -CD138) target cells. Our results demonstrated that the "NK-92 (mCD16) assay" allows convenient and sensitive discrimination of mouse mAbs for their ability to mediate ADCC in a human cellular system. In addition, our results provide examples of dissociation between opsonization and target cell killing through ADCC. These "murinized" human effector cells thus represent a convenient cellular tool for the study of ADCC.

Entities:  

Keywords:  ADCC; CD16; NK; human; lymphocyte; mouse; transfection; xenogenic

Mesh:

Substances:

Year:  2013        PMID: 23770975      PMCID: PMC3906312          DOI: 10.4161/mabs.25077

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  21 in total

1.  Signaling function of reconstituted CD16: zeta: gamma receptor complex isoforms.

Authors:  E Vivier; N Rochet; M Ackerly; J Petrini; H Levine; J Daley; P Anderson
Journal:  Int Immunol       Date:  1992-11       Impact factor: 4.823

2.  Role of macrophages in the augementation of mouse natural killer cell activity by poly I:C and interferon.

Authors:  J Y Djeu; J A Heinbaugh; H T Holden; R B Herberman
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

3.  Apparent sensitivity of human K lymphocytes to the spatial orientation and organization of target cell-bound antibodies as measured by the efficiency of antibody-dependent cellular cytotoxicity (ADCC).

Authors:  J E Christiaansen; S S Burnside; D W Sears
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

4.  Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.

Authors:  R P Junghans; T A Waldmann; N F Landolfi; N M Avdalovic; W P Schneider; C Queen
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

5.  Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.

Authors:  Maria J Polyak; Julie P Deans
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

6.  Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons.

Authors:  M J Brunda; D Rosenbaum
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

7.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors:  M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

8.  Human large granular lymphocytes express high affinity receptors for murine monoclonal antibodies of the IgG3 subclass.

Authors:  C Anasetti; P J Martin; Y Morishita; C C Badger; I D Bernstein; J A Hansen
Journal:  J Immunol       Date:  1987-05-01       Impact factor: 5.422

9.  Crosstalk between human IgG isotypes and murine effector cells.

Authors:  Marije B Overdijk; Sandra Verploegen; Antonio Ortiz Buijsse; Tom Vink; Jeanette H W Leusen; Wim K Bleeker; Paul W H I Parren
Journal:  J Immunol       Date:  2012-09-05       Impact factor: 5.422

10.  Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies.

Authors:  T J Kipps; P Parham; J Punt; L A Herzenberg
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

View more
  15 in total

1.  Nanobody-CD16 Catch Bond Reveals NK Cell Mechanosensitivity.

Authors:  Cristina González; Patrick Chames; Brigitte Kerfelec; Daniel Baty; Philippe Robert; Laurent Limozin
Journal:  Biophys J       Date:  2019-03-23       Impact factor: 4.033

2.  The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.

Authors:  Nathalie Kersual; Véronique Garambois; Thierry Chardès; Jean-Pierre Pouget; Imed Salhi; Caroline Bascoul-Mollevi; Frédéric Bibeau; Muriel Busson; Henri Vié; Béatrice Clémenceau; Christian K Behrens; Pauline Estupina; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  MAbs       Date:  2014       Impact factor: 5.857

3.  Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.

Authors:  Julia Hambach; William Fumey; Tobias Stähler; Anna Josephine Gebhardt; Gerhard Adam; Katja Weisel; Friedrich Koch-Nolte; Peter Bannas
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

4.  pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity.

Authors:  Janessa Wehr; Eden L Sikorski; Elizabeth Bloch; Mary S Feigman; Noel J Ferraro; Trevor R Baybutt; Adam E Snook; Marcos M Pires; Damien Thévenin
Journal:  J Med Chem       Date:  2020-03-30       Impact factor: 7.446

Review 5.  Natural Killer Cells for Therapy of Leukemia.

Authors:  Garnet Suck; Yeh Ching Linn; Torsten Tonn
Journal:  Transfus Med Hemother       Date:  2016-03-22       Impact factor: 3.747

6.  Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.

Authors:  Marie Vincent; Géraldine Teppaz; Laurie Lajoie; Véronique Solé; Anne Bessard; Mike Maillasson; Séverine Loisel; David Béchard; Béatrice Clémenceau; Gilles Thibault; Laure Garrigue-Antar; Yannick Jacques; Agnès Quéméner
Journal:  MAbs       Date:  2014 Jul-Aug       Impact factor: 5.857

Review 7.  Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.

Authors:  Carin I M Dahlberg; Dhifaf Sarhan; Michael Chrobok; Adil D Duru; Evren Alici
Journal:  Front Immunol       Date:  2015-11-30       Impact factor: 7.561

8.  Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.

Authors:  Congcong Zhang; Pranav Oberoi; Sarah Oelsner; Anja Waldmann; Aline Lindner; Torsten Tonn; Winfried S Wels
Journal:  Front Immunol       Date:  2017-05-18       Impact factor: 7.561

Review 9.  Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy.

Authors:  Pingyi Liu; Lingling Chen; Haiyan Zhang
Journal:  J Immunol Res       Date:  2018-09-04       Impact factor: 4.818

10.  CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses.

Authors:  Phoebe E Lewis; Ethan C Poteet; Dongliang Liu; Changyi Chen; Celia C LaBranche; Sherry A Stanfield-Oakley; David C Montefiori; Guido Ferrari; Qizhi Yao
Journal:  Vaccines (Basel)       Date:  2020-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.